Combination of Targeted temperature management and Thrombectomy after acute Ischemic Stroke (COTTIS-2) – a randomised controlled study - COTTIS-2

niversitätsklinikum Freiburg0 个研究点目标入组 400 人开始时间: 2024年2月19日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•oPre-stroke modified Rankin Scale (mRS) 0-2
•oAcute ischemic stroke with NIHSS >5
•oIndication for endovascular treatment (thrombectomy)
•oIntracranial occlusion of the M1 or M2 segment of the middle cerebral artery (MCA) or internal carotid artery (ICA) or tandem occlusion on CT-angiography or MR-angiography
•oTime window:
•-Last seen normal to groin puncture < 6h: native CT or MRI-DWI with Alberta Stroke Program Early CT score (ASPECTS) >5
•-Last seen normal to groin puncture 6-24h or unknown time window: significant mismatch imaging according to the eligibility criteria of the DEFUSE-3 trial:
•- Infarct core <70ml (DWI oder CBF<30% of contralateral site)
•- Penumbra > 15ml (Tmax >6sec)
•- Ratio penumbra/core >1.8
•owith or without iv thrombolysis with rtPA

•oPatients with an intranasal obstruction that prevents complete insertion of the nasal cannula should not be treated with the RhinoChill system.
•oKnown severe hemorrhagic diathesis (International Normalized Ratio (INR) >3.0, partial thromboplastin time (PTT) > 70s, platelet count < 50.000/µl)
•oBrain trauma or neurovascular surgery/intervention <3 months
•oSevere infection
•oPregnant women or women of childbearing potential (women of childbearing potential with negative pregnancy test may be included)
•oKnown cerebral vasculitis
•oProof of bleeding in cerebral CT or MRI (cerebral microbleeds in MRI [hypertensive or in the context of cerebral amyloid angiopathy] is permitted).
•oLife expectancy < 6 months

发起方